Healthcare Investing: Returning to Earth from Outer SpaceX

For a brief moment, SPCX looked like the perfect symbol of this market.

A scarce, iconic, mission-driven growth company came public into an environment still eager to pay almost any price for exposure to the future. The stock opened around $150, quickly traded above $200, and then gave back essentially all of that initial surge, returning toward its opening trade.

That arc is the point. The stock was not repudiated. The company was not dismissed. The premium was.

An Extraordinary Company Is Not the Same as an Extraordinary Stock

That does not mean SpaceX is a bad company. It is plainly an extraordinary company. It does not mean AI is a fad. AI remains one of the most important technological shifts of our lifetimes. And it does not mean the market is suddenly rejecting innovation.

But it does suggest the market is becoming more selective.

There is a difference between an extraordinary company and an extraordinary stock. There is a difference between a technology revolution and a price that already discounts too much of that revolution. There is a difference between believing in a theme and assuming that every asset attached to that theme can compound from any valuation.

Memory: Real Strength, Commodity Economics

Over the past month, the AI, technology, and QQQ complex has shown signs of fatigue. The weakness has not been uniform, and it certainly has not been a classic risk-off move. There are still pockets of significant strength, particularly in semiconductors and memory. Micron has continued to benefit from an unusually favorable supply-demand environment, with AI infrastructure demand overwhelming available supply and driving very strong earnings power.

That strength is real. It should not be dismissed. Memory is essential to the current AI buildout, and the near-term economics for the leading suppliers have been exceptional.

But it is also important to remember what memory is. These are ultimately commodity products. When supply is tight and demand is urgent, commodity businesses can generate extraordinary profitability. But scarcity-driven profitability is different from structural pricing power. The question is not whether current earnings are strong. They are. The question is how much of today’s favorable imbalance the market is now willing to capitalize.

The tells will be straightforward. If supply remains constrained, customer commitments extend, pricing holds, and AI workloads keep consuming more memory intensity, the current cycle can last longer than many expect. But if new supply arrives, customers push back on pricing, inventory builds, or more efficient AI architectures begin reducing dependence on the most constrained memory components, the market will have to reassess how much of today’s earnings power is truly sustainable.

Who Captures the Economics, and at What Valuation

That is the broader issue with the AI trade today. The question is no longer simply, “Is AI real?” It is real. Nor is the question, “Will AI matter?” It will matter enormously. The better question is: who captures the economics, for how long, and at what valuation?

That question becomes more important after the enormous move in the semiconductor complex. Semiconductors now represent roughly 18% of the S&P 500. That is a remarkable concentration of market capitalization in a single profit pool, especially one already reflecting years of extraordinary growth expectations. From here, continued upside requires more than good fundamentals. It requires fundamentals that are strong enough to exceed a very demanding consensus and justify an increasingly large share of the market.

This is not an argument to abandon technology. It is an argument that the market is becoming more discerning. The easy phase of the AI trade was the narrative phase. The next phase is likely to be more about returns on capital, earnings durability, valuation, and proof.

Healthcare Starts to Work Again

Against that backdrop, Healthcare’s recent outperformance is notable.

Healthcare has started to work again as AI and technology have cooled. We do not view that as random, and we have been anticipating this broadening. The sector entered this period with depressed relative valuations, low investor enthusiasm, and years of underperformance versus the technology complex. That created a very different setup from AI infrastructure, where expectations were already extremely high.

We should be honest about the nature of the Healthcare call. It is partly a fundamentals call, but it is also an expectations and valuation call. We are not arguing that every Healthcare company suddenly has better growth than every AI company. We are arguing that the market has been applying a much higher standard to Healthcare than to the dominant technology leaders, while discounting several things that are now beginning to improve.

Valuations across Healthcare are attractive relative to the market. Growth outlooks are stabilizing and, in some cases, accelerating. Innovation remains extraordinary. Demographics and medical demand provide powerful long-term support. And after several years in which policy uncertainty was a persistent overhang, the environment appears less threatening than many investors feared.

That combination is important. Low expectations do not create a bull market by themselves. But low expectations plus improving evidence can be powerful.

Pharma and Managed Care Lead

The initial phase of the Healthcare recovery has been led by large-cap Pharma and Managed Care, two areas where cash flow visibility, valuation support, and improving expectations have mattered most. But the opportunity in Healthcare is not simply defensive. The sector is also home to some of the most important innovation in the economy.

Large Pharma has worked because the market is beginning to recognize that the group is more than defensive cash flow. The best companies have strong franchises, visible earnings, meaningful pipeline optionality, and the balance sheet capacity to supplement internal innovation with external assets. When expectations are low, companies do not need perfection to re-rate.

Managed Care has worked for a different reason. The group had been pressured by medical cost concerns, utilization uncertainty, policy risk, and investor fatigue. But the market is now beginning to look through some of that pressure as pricing and medical cost trends become more manageable. This is not a clean or simple recovery. But the perception has shifted from “uninvestable” to “recoverable,” and that shift can be meaningful when valuations already reflect a great deal of skepticism.

Can the Leadership Broaden?

The more interesting question now is whether Healthcare leadership can broaden.

So far, it has not broadened evenly. MedTech and Life Science Tools have meaningfully lagged, and for understandable reasons. In MedTech, investors are still debating procedure growth, hospital capital spending, China exposure, pricing, and margin recovery. In Life Science Tools, the market is still waiting for clearer signs of bioprocessing recovery, stabilization in China, better instrument demand, and a healthier funding environment.

But both areas may be positioned to catch up if earnings begin to confirm stabilization.

In MedTech, the long-term drivers remain strong: aging demographics, minimally invasive procedures, robotic surgery, structural heart innovation, electrophysiology, orthopedics, and diabetes technology. In Life Science Tools, the industry remains essential to the broader innovation engine of medicine, from biologics and diagnostics to bioproduction and next-generation therapies. The issue has not been the long-term relevance of these businesses. The issue has been confidence in the near-term growth trajectory.

Why Earnings Season Matters

That is why the upcoming earnings season is so important.

Healthcare’s recent outperformance has been supported by relative valuation, improving sentiment, and a market looking for alternatives to crowded technology leadership. To persist, it now needs confirmation from the numbers. Pharma needs to show that growth drivers and pipelines are broadening. Managed Care needs to show that pricing and medical cost trends are stabilizing. MedTech needs to show that procedure volumes, margins, and capital spending remain healthy. Life Science Tools needs to show that the long-awaited recovery is becoming visible rather than merely hoped for.

We do not expect the sector to move as one. In fact, we expect dispersion to increase. That is healthy. A better Healthcare tape does not mean every Healthcare stock should work. It means the market may finally be willing to reward companies with improving fundamentals, credible growth, strong competitive positions, and reasonable valuations.

That is the environment we have been positioning for.

A Higher Burden of Proof

The lesson of the last month is not that AI is over. It is that even the most powerful themes eventually face a higher burden of proof. Markets begin to distinguish between innovation and valuation, between revenue growth and earnings power, between scarcity and sustainability, and between compelling stories and attractive forward returns.

Healthcare offers a different version of innovation. It is less about data centers and more about patients. Less about GPUs and more about new standards of care. Less about monetizing future productivity and more about improving health, extending life, and building businesses around essential demand.

SpaceX may still reach extraordinary heights as a company. AI may still transform the economy. But for investors, the past month has been a reminder that price matters, expectations matter, and leadership changes when the market begins demanding proof.

We think Healthcare is well positioned for that kind of market.

The sector is cheaper than the market, more innovative than it is often perceived to be, supported by powerful long-term demand drivers, and entering an earnings season that can provide the evidence investors need. If that evidence comes through, the recent rotation into Healthcare may prove to be more than a short-term defensive trade.

It may be the beginning of a broader return to fundamentals.